Acadia Leaps Toward the Finish Line

After an incredible performance in late March, when shares of Acadia Pharmaceuticals jumped up 23%, they have once again exploded today, up 40% intraday. What's behind these massive leaps for this pharmaceutical company, and is there more on the way? In this video, Motley Fool health-care analyst David Williamson tells investors about the drug that has Acadia investors so excited, why it has so many competitive advantages, and what investors need to watch from here.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


The article Acadia Leaps Toward the Finish Line originally appeared on Fool.com.

David Williamson owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Learn about investing from the comfort of your own home.

Portfolio Basics

Take the first steps to building your portfolio.

View Course »

Investment Strategies

Learn the strategies you need to build a winning portfolio

View Course »

Add a Comment

*0 / 3000 Character Maximum